Results 11 to 20 of about 76,618 (225)

Etanercept

Turkderm Turkish Archives of Dermatology and Venereology, 2022
Etanercept is a recombinant human receptor fusion protein that suppresses, as a contestant, the interaction of TNF-α with cell surface receptors. It received FDA approval in 1999 to be used in children older than 2 years for the treatment of juvenile ...
Sibel Alper
doaj   +2 more sources

Etanercept

Reactions Weekly, 2012
Hoofnagle JH.
europepmc   +5 more sources

Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination

RMD Open, 2021
Objectives We examined patient-reported outcomes (PROs) in The Study of Etanercept And Methotrexate in Patients with Psoriatic Arthritis (PsA); a 48-week, phase 3, randomised controlled trial that compared outcomes with methotrexate (MTX) monotherapy ...
Vibeke Strand, Ervant J Maksabedian Hernandez, Bradley S Stolshek, Lyrica X H Liu, David H Collier, Gregory Kricorian   +5 more
doaj   +1 more source

Etanercept Ameliorates Cardiac Fibrosis in Rats with Diet-Induced Obesity

Pharmaceuticals, 2021
Diet-induced obesity (DIO) is considered the main risk factor for cardiovascular diseases. Increases in the plasma levels of tumor necrosis factor alpha (TNF-α) is associated with DIO.
Chia-Chen Hsu, Yingxiao Li, Chao-Tien Hsu, Juei-Tang Cheng, Mang-Hung Lin, Kai-Chun Cheng, Shang-Wen Chen   +6 more
doaj   +1 more source

Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up. [PDF]

PLoS ONE, 2018
OBJECTIVES:To determine the percentage non-adherence to etanercept in patients with rheumatoid arthritis during three years of follow-up. METHODS:During study visits in this prospective cohort study, blood samples were taken to determine serum etanercept
E H Vogelzang, R C F Hebing, M T Nurmohamed, A W R van Kuijk, J W F Kruijff, M J l'Ami, C L M Krieckaert, G Wolbink   +7 more
doaj   +1 more source

Effect of etanercept on post-traumatic proliferative vitreoretinopathy [PDF]

International Journal of Ophthalmology, 2019
AIM: To evaluate the safety and efficacy of intravitreal etanercept in the inhibiting of proliferative vitreoretinopathy (PVR) in a model of penetrating ocular injury.
Xiao-Feng Chen, Mei Du, Xiao-Hong Wang, Hua Yan   +3 more
doaj   +1 more source

Etanercept biosimilars [PDF]

Rheumatology International, 2014
Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are undergoing clinical trials, with the promise of being ...
Azevedo, Valderilio F., Galli, Nathalia, Kleinfelder, Alais, D’Ippolito, Julia, Urbano, Paulo C. M.   +4 more
openaire   +2 more sources

Maternal and Fetal-Placental Effects of Etanercept Treatment During Rats’ Pregnancy

Frontiers in Physiology, 2022
Etanercept is a tumor necrosis factor alpha (TNF-α) inhibitor chronically used to treat autoimmune diseases. However, the use of etanercept during pregnancy still needs to be further investigated.
Gabriel Gomes Araujo, Rinaldo Rodrigues dos Passos Junior, Rosaline Rocha Lunardi, Gustavo Tadeu Volpato, Thaigra Sousa Soares, Fernanda Regina Giachini, Fernanda Regina Giachini, Victor Vitorino Lima   +7 more
doaj   +1 more source

Etanercept attenuates myocardial ischemia/reperfusion injury by decreasing inflammation and oxidative stress. [PDF]

PLoS ONE, 2014
The protective role of etanercept in myocardial ischemia/reperfusion is not well understood. The aim of this study was to investigate whether etanercept modulates neutrophil accumulation, TNF-α induction and oxidative stress in an ischemia/reperfusion ...
Mei Yang, Jianchang Chen, Jing Zhao, Mei Meng   +3 more
doaj   +1 more source

Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis [PDF]

, 2013
Anti-tumor necrosis factor alpha (anti-TNF) biologic therapy is a widely used treatment for rheumatoid arthritis (RA). It is unknown why some RA patients fail to respond adequately to anti-TNF therapy, which limits the development of clinical biomarkers ...
A Parker, AI Catrina, AL Price, Alison Motsinger-Reif, AM van Gestel, Ann W. Morgan, Anne Barton, Anthony G. Wilson, Atsuo Taniguchi, B Devlin, Barbara E. Stranger, BE Stranger, BJ Scallon, C Liu, C Miceli-Richard, Chikashi Terao, Corinne Miceli, Cornelia F. Allaart, D Aeberli, D Plant, D Plant, DL Scott, Dorothee Diogo, EA Stahl, EA Stahl, EJ Toonen, Eli A. Stahl, Elizabeth W. Karlson, FM Batliwalla, Fumihiko Matsuda, Gert Jan Wolbink, GM Cooper, Gosia Trynka, H Canhao, Helena Canhao, Henk-Jan Guchelaar, Hisashi Yamanaka, IB McInnes, Irene E. van der Horst-Bruinsma, J Agnholt, J Cui, J Ernst, J Marchini, J. Bart A. Crusius, Jing Cui, Johan Askling, John D. Isaacs, João Eurico Fonseca, Katsunori Ikari, Kimme L. Hyrich, Koichiro Ohmura, L Klareskog, L Padyukov, Larry W. Moreland, LD Ward, Leonid Padyukov, Lindsey A. Criswell, M Martin, Manik Kuchroo, Marieke E. Doorenspleet, Marieke Herenius, Marieke J. H. Coenen, Mart van de Laar, Maša Umiċeviċ Mirkov, Michael E. Weinblatt, MJ Coenen, ML Prevoo, MM Soliman, Namrata Gupta, Nancy A. Shadick, Niek de Vries, O Stegle, Paul-Peter Tak, Peter K. Gregersen, Philip L. De Jager, PI de Bakker, Piet L. C. M. van Riel, PL De Jager, R Prajapati, Rene E. M. Toes, RM Plenge, Robert M. Plenge, Robert P. Kimberly, S Gudbrandsdottir, S Purcell, S. Louis Bridges, SA Gauthier, Saedis Saevarsdottir, Sara Wedrén, SG Tangye, Shigeki Momohara, Soumya Raychaudhuri, Tom W. J. Huizinga, Towfique Raj, Tsuneyo Mimori, Xavier Mariette, Y Okada, Yukinori Okada   +97 more
core   +22 more sources